Table 1.
Baseline characteristics of the patients.
| Characteristic | Cisplatin and vinorelbine (N = 67) | Cisplatin and gemcitabine (N = 67) |
|---|---|---|
| Age (yr) | ||
| Median | 58.9 | 61.6 |
| Range | 34–79 | 44–78 |
| Sex (% of patients) | ||
| Female | 4.5 | 1.49 |
| Male | 95.5 | 98.5 |
| Smoking status (% of patients) | ||
| Nonsmoker | 7.5 | 2.9 |
| <10 pack/year | 0 | 0 |
| 10–20 pack/year | 7.5 | 8.9 |
| 21–30 pack/year | 20.9 | 25.3 |
| >30 pack/year | 64.1 | 62.6 |
| Performance status (% of patients) | ||
| 0 | 5.9 | 5.9 |
| 1 | 47.7 | 47.7 |
| 2 | 46.2 | 46.2 |
| Disease stage (% of patients) | ||
| IIIB | 58.2 | 71.6 |
| IV | 41.8 | 28.3 |
| Histological type (% of patients) | ||
| Squamous cell | 64.1 | 79.1 |
| Adenocarcinoma | 19.5 | 13.4 |
| Undifferentiated NSCLC | 16.4 | 7.4 |
| Metastasis sites (no. of patients) | ||
| 1 | 32 | 20 |
| 2 | 7 | 6 |
| ≥3 | 3 | 2 |
| Brain metastasis (no. of patients) | 12 | 7 |
*
Mann-Whitney U test,
**
Pearson chi-square test.
Abbreviations: CV: Cisplatin-Vinorelbine; CG: Cisplatin-Gemcitabine; NSCLC: Non-small cell lung carcinoma.